Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

imzia®, 1% placebo), rash (3% Cimzia®, 1% placebo), acute bronchitis (3% Cimzia®, 1% placebo), fatigue (3% Cimzia®, 1% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving Cimzia® than in controls. These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs. Patients receiving Cimzia® 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving Cimzia® 200mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for Cimzia® and 2.5% for placebo.

Please see full prescribing information at www.cimzia.com/rheumatoidarthritis/pdf/Prescribing_Information.pdf

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10,000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competi
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of the  ...  report to their offering.       (Logo: ... one of the fastest-growing segments in the chromatography ... in 2013, and expected to reach $2.0 billion ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... cells are undifferentiated biological cells that can differentiate into ... more stem cells. Stem cell therapy can be applied ... hematological system disease), nervous system diseases, damage or lesion ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... not the size of the eyespots on a male ... Instead, females are attracted to the "sparkle" created by ... at the center of eyespots, according to new research ... be published online June 29 in the Proceedings of ...
... between the two viruses could one day lead to ... researcher has discovered an unexpected link between the viruses ... an experimental strain of the human AIDS virus appear ... version of the disease as those immunized with the ...
... in a single gene can result in two ... to frequent or unusually severe infections, according to ... Nature Genetics. The discovery may lead to new ... A (IgA) deficiency and common variable immunodeficiency (CVID). ...
Cached Biology News:Female butterflies go for sparkle -- not size -- when choosing to mate 2Female butterflies go for sparkle -- not size -- when choosing to mate 3UF scientist finds unexpected link between cat and human AIDS viruses 2Agreement will speed research on microbicides for women 2Agreement will speed research on microbicides for women 3
Request Info...
R26.4C...
... x H): 17 3/4" x 8 ... slidesTime: Programmable 0 - 100 hoursControl: Programmable ... steps 40 user programmable protocols 3 operating ... Rapid temperature ramp-up from 37 - 95C ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: